All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

somatostatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
growth hormone derivatives	2997	38916-34-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: somatostatin aminopan growth hormone release-inhibiting factor somatotropin release-inhibiting hormone SRIF-14

A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Molecular weight: 1637.90 Formula: C76H104N18O19S2 CLOGP: -1.45 LIPINSKI: 3 HAC: 37 HDO: 22 TPSA: 613.23 ALOGS: -4.90 ROTB: 26

Drug dosage:

Dose	Unit	Route
6	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Administration site abscess	49.49	42.81	5	320	21	90628101
Administration site induration	49.49	42.81	5	320	21	90628101
Administration site discharge	48.61	42.81	5	320	26	90628096
Administration site odour	46.75	42.81	5	320	40	90628082
Administration site haemorrhage	44.26	42.81	5	320	69	90628053

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastric varices	48.82	43.48	8	403	682	42620242

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastric varices	49.94	33.91	8	717	871	110587703
Administration site abscess	46.45	33.91	5	720	21	110588553
Administration site discharge	45.57	33.91	5	720	26	110588548
Administration site odour	44.30	33.91	5	720	35	110588539
Administration site induration	43.39	33.91	5	720	43	110588531
Administration site haemorrhage	43.39	33.91	5	720	43	110588531
Malignant neoplasm progression	41.52	33.91	21	704	174546	110414028
Injection site cyst	37.69	33.91	5	720	145	110588429
Portal hypertension	36.73	33.91	9	716	8628	110579946
Buttock injury	35.84	33.91	5	720	212	110588362
Pancreatic neuroendocrine tumour	35.43	33.91	6	719	917	110587657

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01CB01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Somatostatin and analogues
MeSH PA	D006728	Hormones

Related Drugs by ATC class:

H01CB Somatostatin and analogues 4 drugs

lanreotideoctreotidepaltusotinepasireotide

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.02	acidic
pKa2	12.17	acidic
pKa3	12.57	acidic
pKa4	12.85	acidic
pKa5	13.02	acidic
pKa6	13.2	acidic
pKa7	13.52	acidic
pKa8	13.6	acidic
pKa9	13.77	acidic
pKa10	13.88	acidic
pKa11	11.11	Basic
pKa12	10.51	Basic
pKa13	8.46	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Somatostatin receptor type 2	GPCR	P30874	SSR2_HUMAN	AGONIST	Ki	10.46		CHEMBL	IUPHAR
Somatostatin receptor type 3	GPCR	P32745	SSR3_HUMAN	AGONIST	Ki	10		CHEMBL	IUPHAR
Somatostatin receptor type 5	GPCR	P35346	SSR5_HUMAN	AGONIST	Ki	9.85		CHEMBL	IUPHAR
Somatostatin receptor type 4	GPCR	P31391	SSR4_HUMAN	AGONIST	Ki	9.23		CHEMBL	IUPHAR
Somatostatin receptor type 1	GPCR	P30872	SSR1_HUMAN	AGONIST	Ki	9.54		CHEMBL	IUPHAR
Somatostatin receptor	GPCR		SSR5_MOUSE SSR1_MOUSE SSR2_MOUSE SSR3_MOUSE SSR4_MOUSE		IC50	5.89		CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		IC50	8.22		CHEMBL
Somatostatin receptor	GPCR		SSR1_RAT SSR2_RAT SSR3_RAT SSR4_RAT SSR5_RAT		IC50	9.70		CHEMBL
Delta-type opioid receptor	GPCR		OPRD_RAT		IC50	5.70		CHEMBL
Somatostatin receptor type 2	GPCR		SSR2_MOUSE		IC50	9.55		CHEMBL
Somatostatin receptor type 3	GPCR		SSR3_MOUSE		IC50	10.10		CHEMBL
Somatostatin receptor type 5	GPCR		SSR5_RAT		IC50	9.07		CHEMBL

External reference:

ID	Source
N0000007997	NUI
D07431	KEGG_DRUG
C0037659	UMLSCUI
CHEBI:64628	CHEBI
CHEMBL1823872	ChEMBL_ID
D013004	MESH_DESCRIPTOR_UI
DB09099	DRUGBANK_ID
4311	INN_ID
6E20216Q0L	UNII
16129706	PUBCHEM_CID
9939	RXNORM
005072	NDDF
49722008	SNOMEDCT_US
57819002	SNOMEDCT_US
2019	IUPHAR_LIGAND_ID

Pharmaceutical products:

None